Related by context. All words. (Click for frequent words.) 73 metastatic CRC 72 metastatic hormone refractory 71 mRCC 71 recurrent glioblastoma multiforme 71 stage IIIB IV 71 HER2 positive metastatic breast 70 assessing T DM1 70 recurrent NSCLC 70 metastatic bladder 70 hepatocellular cancer 70 tumors GIST 70 metastatic colorectal 70 resistant hormone refractory 69 multiple myeloma MM 69 systemic ALCL 69 stage IIIb IV 69 leukemia AML 69 TTF Therapy 69 metastatic renal 69 metastatic renal cell carcinoma 69 relapsed MM 69 advanced carcinoid 69 metastatic castrate resistant 68 metastatic kidney 68 KRAS wild 68 metastatic castration resistant 68 relapsed acute lymphoblastic 68 refractory metastatic 68 MabThera Rituxan 68 refractory metastatic colorectal cancer 68 metastatic CRPC 68 lintuzumab SGN 68 Brentuximab Vedotin SGN 68 TroVax ® 68 Hepatocellular Carcinoma HCC 68 Prednisone Against Refractory 68 ELACYT 68 opioid induced constipation OIC 68 metastatic gastric 68 hormone refractory metastatic prostate 68 taxane refractory 68 Phase #/#a trial 68 nonmetastatic 68 malignant pleural mesothelioma 67 achieved CCyR 67 gemcitabine chemotherapy 67 advanced metastatic prostate 67 biliary tract cancer 67 Troxatyl 67 metastatic pancreatic 67 gastrointestinal stromal tumor GIST 67 metastatic GIST 67 IMA# 67 heavily pretreated 67 dasatinib Sprycel ® 67 HRPC 67 ErbB2 positive 67 advanced hepatocellular carcinoma 67 relapsed refractory multiple myeloma 67 lymphoid malignancies 67 relapsing remitting MS RRMS 67 refractory acute lymphoblastic 67 Nexavar sorafenib 67 IV melanoma 67 Follicular Lymphoma 67 unresectable stage 67 refractory AML 67 Aflibercept 67 BRAF V# mutation 67 Hormone Refractory Prostate Cancer 67 relapsed leukemia 67 KRAS mutations occur 67 hematological cancers notably 67 pancreatic carcinoma 67 axitinib 67 evaluating tivozanib 67 nonsmall cell lung cancer 67 EGFR TKI 67 castrate resistant prostate cancer 67 metastatic malignant melanoma 67 platinum refractory 67 pediatric acute lymphoblastic 67 unresectable locally advanced 67 PSMA ADC 67 relapsed multiple myeloma 67 naïve HCV 67 Cutaneous T 67 refractory chronic lymphocytic 66 Jevtana 66 polycythemia vera essential thrombocythemia 66 MKC# MT 66 Annamycin 66 BRAF mutant 66 evaluating T DM1 66 registrational trial 66 INCB# [001] 66 Bayer HealthCare Onyx Pharmaceuticals 66 including eniluracil ADH 66 essential thrombocythemia ET 66 relapsed refractory AML 66 Gleevec resistant 66 indolent NHL 66 refractory chronic myeloid 66 hormone refractory prostate cancer 66 myelodysplastic myeloproliferative diseases 66 forodesine 66 stage IIIb 66 Velcade bortezomib 66 leukemia ALL 66 Relapsed Refractory 66 dasatinib Sprycel 66 pertuzumab 66 pancreatic adenocarcinoma 66 refractory acute myeloid 66 untreated metastatic colorectal 66 underwent surgical resection 66 alvespimycin 66 non squamous 66 BRIM3 66 Lupus Nephritis 66 Hodgkin lymphoma HL 66 cabazitaxel 66 rALLy 66 underwent resection 66 anthracycline taxane 66 castration resistant hormone refractory 66 EGFR mutation positive 66 antibody MAb 66 mitoxantrone plus 66 completely resected 66 castrate resistant 66 Allovectin 7 66 CYT# potent vascular disrupting 66 oral ridaforolimus 66 pegylated interferon alpha 66 medically inoperable 66 VEGFR2 inhibitor 66 phase IIb study 66 alemtuzumab Campath 66 hematological malignancy 66 Amrubicin 66 Roche Herceptin 66 AEG# 66 recurrent metastatic 66 EndoTAGTM 1 66 LymphoStat B belimumab 66 phase IIb clinical 66 Tesmilifene 65 anthracycline containing 65 receptor tyrosine kinase inhibitor 65 childhood acute lymphoblastic 65 Ixempra 65 Gastrointestinal Stromal Tumors 65 metaglidasen 65 metastatic colorectal carcinoma 65 previously untreated follicular 65 LHRH receptor positive 65 Epothilone D 65 Combination REOLYSIN R 65 whose tumors overexpress 65 clinically localized prostate 65 leukemia APL 65 elotuzumab 65 recurrent malignant glioma 65 mCRPC 65 pemphigus vulgaris 65 commercialize deforolimus 65 systemic anaplastic large 65 advanced unresectable 65 anti EGFR antibody 65 refractory colorectal cancer 65 HER2 amplified 65 BRIM2 65 Myelodysplastic Syndrome MDS 65 Gleevec Glivec 65 antiretroviral naïve 65 ACTEMRA TM 65 cetuximab Erbitux 65 imatinib Gleevec ® 65 PANVAC VF 65 oral clodronate 65 Kit CD# positive 65 adult chronic ITP 65 TNF blocker therapy 65 trastuzumab DM1 65 AML acute myeloid 65 IV NSCLC 65 Medullary thyroid cancer 65 follicular Non Hodgkin 65 common hematologic malignancy 65 lymphoma CTCL 65 relapsed SCLC 65 glufosfamide 65 bladder ovarian 65 gastrointestinal stromal tumors 65 humanized interleukin 6 65 BRAF inhibitor 65 Metastatic Colorectal Cancer 65 novel VDA molecule 65 Renal Cell Carcinoma RCC 65 lumiliximab 65 Folfox 65 chronic HBV 65 metastatic sarcomas 65 MCyR 65 cytogenetic responses 65 SCCHN 65 Alessandro Riva 65 IIa trial 65 FOLFOX6 65 Stage IIIb 65 unresectable liver cancer 64 advanced HER2 positive 64 recurrent glioblastoma 64 metastatic HRPC 64 metastatic carcinoid 64 hormone refractory 64 Chronic lymphocytic leukemia 64 Ceflatonin 64 indolent follicular non 64 alpha folate receptor 64 Daclizumab 64 placebo dexamethasone 64 Acute Myelogenous Leukemia AML 64 OMP #R# 64 Naive Patients 64 Cholangiocarcinoma 64 smoldering myeloma 64 recurrent GBM 64 Adjuvant Treatment 64 non metastatic osteosarcoma 64 Relapsed Multiple Myeloma 64 CTAP# Capsules 64 prostate cancer HRPC 64 Intravenous CP 64 Phase IIa trials 64 HBeAg negative 64 SNT MC# 64 MAGE A3 ASCI 64 Phase #b/#a clinical 64 ASONEP TM 64 anti PlGF 64 Peginterferon alfa 2b 64 non squamous NSCLC 64 phase IIb trial 64 5-fluorouracil/leucovorin 64 TBC# 64 Ophena TM 64 cutaneous T 64 differentiated thyroid 64 Amgen Neulasta R 64 SPRYCEL ® 64 SNT-MC#/idebenone 64 5 fluorouracil leucovorin 64 gemcitabine carboplatin 64 eosinophilic asthma 64 HBeAg negative patients 64 Acute myelogenous leukemia 64 Pegylated Interferon 64 glioblastoma multiforme GBM 64 gemcitabine Gemzar ® 64 refractory NSCLC 64 refractory cutaneous T 64 lupus nephritis 64 Quinamed 64 Glioblastoma Multiforme 64 advanced medullary thyroid 64 blastic phase 64 chemosensitizer 64 GVAX Immunotherapy 64 refractory APL 64 metastatic RCC 64 metastatic androgen independent 64 drug figitumumab 64 untreated metastatic pancreatic 64 advanced NSCLC 64 hepatitis C HCV 64 Temsirolimus 64 androgen independent 64 Merck KGaA Erbitux 64 Amgen Neulasta ® 64 Randomized Phase 64 non resectable metastatic 64 ixabepilone 64 evaluating picoplatin 64 Solazed 64 AAG geldanamycin analog 64 EGFR expressing mCRC 64 sunitinib Sutent 64 gefitinib Iressa 64 bone marrow reticulin deposition 64 omacetaxine mepesuccinate 64 mapatumumab 64 refractory Hodgkin 64 mCRC patients 64 plus gemcitabine 64 interferon gamma 1b 64 Acute Myeloid Leukaemia AML 64 Vandetanib 64 Phase Ib IIa 64 PegIFN RBV 64 minimally symptomatic 64 relapsed AML 64 cisplatin chemotherapy 64 RSR# 64 FOLFIRI alone 64 Phase IIb trials 64 smoldering multiple myeloma 64 OncoVEX GM CSF 64 cyclophosphamide chemotherapy 64 initiated Phase Ib 64 histone deacetylase HDAC inhibitor 64 Doxil ® 64 docetaxel Taxotere 63 advanced epithelial ovarian 63 sunitinib malate 63 CIMZIA TM certolizumab pegol 63 Taxotere ® 63 metastatic malignant 63 IAP inhibitor 63 bortezomib refractory 63 breast pancreatic 63 relapsed GBM 63 cell lymphoma CTCL 63 gastrointestinal stromal 63 MDS AML 63 deCODE ProstateCancer TM 63 elacytarabine 63 recurrent colorectal cancer 63 MGd 63 Idiopathic pulmonary fibrosis 63 non hodgkin lymphoma 63 Pivotal Phase III 63 Flu Cy 63 taxane therapy 63 Phase 2b Clinical Trial 63 myelodysplastic syndrome MDS 63 AVASTIN 63 Newly Diagnosed Chronic Myeloid 63 Alemtuzumab 63 TTR amyloidosis 63 trastuzumab Herceptin R 63 Stage IIB 63 metastatic colorectal cancer 63 progressive metastatic prostate 63 Virulizin ® 63 iniparib BSI 63 refractory CLL 63 Newly Diagnosed Patients 63 NMIBC 63 colorectal cancer liver metastases 63 oblimersen 63 Pemetrexed 63 estramustine 63 budesonide foam 63 Bezielle 63 treatment naïve genotype 63 anthracyclines taxanes 63 myeloproliferative disorders 63 trastuzumab DM1 T DM1 63 Lung transplantation 63 adecatumumab 63 lenalidomide Revlimid R 63 opioid induced bowel dysfunction 63 Hedgehog Pathway Inhibitor 63 HER2 positive cancers 63 galiximab 63 Arzerra ofatumumab 63 generation PNP inhibitor 63 Pegasys plus Copegus 63 Cloretazine ® 63 DCVax ® Brain 63 operable breast cancer 63 GW# [003] 63 CLL SLL 63 Systemic Sclerosis 63 virus HCV protease inhibitor 63 CIMZIA ™ 63 Dacogen injection 63 recurrent glioblastoma multiforme GBM 63 Tarceva erlotinib 63 receiving chemoradiation therapy 63 Panzem R NCD 63 BR.# 63 Sudhir Agrawal D.Phil 63 squamous histology 63 Aplidin 63 refractory gout 63 Chronic Lymphocytic Leukemia CLL 63 neovascular diseases 63 cytoreduction 63 BENLYSTA TM 63 generation radiolabeled antibody 63 Bayer Nexavar 63 stage IIIB 63 Meets Primary Endpoint 63 Neuvenge 63 Malignant Melanoma 63 CCR9 antagonist 63 multi kinase inhibitor 63 taxane chemotherapy 63 de novo kidney transplant 63 relapsed Hodgkin lymphoma 63 huN# DM1 63 docetaxel Taxotere R 63 RhuDex TM 63 virus HCV infection 63 AA Amyloidosis 63 papillary renal cell carcinoma 63 pazopanib 63 TELINTRA R 63 Philadelphia Chromosome Positive 63 EndoTAG TM -1 63 motesanib 63 hypereosinophilic syndrome 63 Cabazitaxel 63 iniparib 63 demonstrated antitumor activity 63 HER2 + 63 Vertex telaprevir 63 HIV coinfected 63 AGILECT R 63 carcinoma HCC 63 capecitabine Xeloda 63 vinflunine 63 FOLFOX6 chemotherapy regimen 63 Phase IIIb clinical 63 Alocrest 63 chlorambucil 63 Theratope 63 sorafenib Nexavar ® 63 dose cohort 63 pegylated liposomal doxorubicin 63 RhuDex R 63 thetreatment 63 BCIRG 63 Phase Ib II 63 VELCADE melphalan 63 intravenous RSD# 63 Kamada AAT 63 refractory ovarian cancer 63 metastatic lung cancer 63 Temodar ® 63 Torisel 63 psoriatic arthritis PsA 63 Cell Lymphoma 63 fallopian tube carcinoma 63 Chronic lymphocytic leukemia CLL 63 mCRC 63 Fx #A 63 pT3 63 NSCLC 63 hormone receptor negative 63 Natalizumab 63 leading oral taxane 63 crizotinib PF # 63 acyclovir Lauriad R 63 p# biomarker 63 minimally symptomatic metastatic castrate 63 cutaneous T cell 63 relapsed ovarian cancer 63 CR nPR 62 Sutent sunitinib 62 invasive lobular 62 psoriasis rheumatoid arthritis 62 temsirolimus 62 regorafenib 62 Evoltra ® 62 enzastaurin 62 kidney urologic 62 treatment naive genotype 62 XL# SAR# 62 rituximab refractory 62 oral FTY# 62 ThermoDox R 62 ALN VSP Phase 62 mutated KRAS 62 haematologic 62 B CLL 62 radiation chemoradiation 62 vidofludimus 62 Ph + acute lymphoblastic 62 alfa 2a 62 sorafenib tablets 62 Castration Resistant Prostate Cancer 62 interferon beta therapy 62 immunotherapeutic agent 62 patients evaluable 62 severe hypercholesterolemia 62 Roche Actemra 62 chronic lymphocytic leukemia CLL 62 paclitaxel Taxol ® 62 Romidepsin 62 non nucleoside inhibitor 62 generation NNRTI 62 tanespimycin 62 Campath alemtuzumab 62 taxane chemotherapy administered 62 dacarbazine DTIC 62 essential thrombocythemia 62 low dose cytarabine 62 postoperative chemotherapy 62 Acute myeloid leukemia 62 HGS ETR1 62 non splenectomized 62 Glufosfamide 62 alkylating agent 62 BRAF mutated 62 ara C 62 elderly myelodysplastic syndromes 62 Azilect ® 62 erlotinib Tarceva ® 62 drug Treanda 62 Brain metastases 62 partial remissions 62 chemoradiation therapy 62 PROSTVAC VF 62 Ribavirin causes 62 adjuvant tamoxifen 62 untreated metastatic melanoma 62 Acute Myeloid Leukemia AML 62 Metastatic Renal Cell Carcinoma 62 BRAF V#E mutation 62 Advanced Melanoma 62 adalimumab Humira 62 docetaxel Injection Concentrate 62 IV malignant melanoma 62 ganetespib 62 leukemia multiple myeloma 62 R#/MEM # 62 advanced metastatic renal 62 sorafenib Nexavar 62 Phase III randomized controlled 62 tumor lysis syndrome 62 Atypical Hemolytic Uremic Syndrome 62 peritoneal carcinomatosis 62 compound INCB# 62 allogeneic bone marrow 62 medullary thyroid cancer 62 Vicriviroc 62 IRX 2 62 neuroendocrine cancers 62 unresectable Stage III 62 Her2 positive 62 dose escalation phase 62 malignant pleural mesothelioma MPM 62 Pivotal Phase 62 interferon ribavirin 62 MT#/MEDI-# 62 Archexin 62 refractory CTCL 62 BARACLUDE ® 62 induced macular edema 62 Gleevec imatinib 62 PROSTVAC TM 62 cetuximab Erbitux R 62 Tasimelteon 62 infusional 5-FU/LV 62 investigational oral hepatitis C 62 achieved sustained virological 62 haematologic malignancies 62 hepatorenal syndrome 62 3 registrational trial 62 bladder carcinoma 62 Omacetaxine 62 Myelodysplasia 62 reduce serum phosphate 62 ospemifene 62 CIMZIA TM 62 aflibercept 62 Crizotinib 62 unresectable tumors 62 follicular lymphoma FL 62 8mg/kg 62 panobinostat 62 IV metastatic melanoma 62 MET inhibitor 62 chronic eosinophilic leukemia 62 ZACTIMA 62 Alzhemed TM 62 irinotecan chemotherapy 62 deforolimus 62 IIb clinical trial 62 oral picoplatin 62 abiraterone acetate 62 Abiraterone acetate 62 Xelox 62 ribavirin RBV 62 doublet chemotherapy 62 biliary cancer 62 FOLFOX chemotherapy 62 bendamustine 62 Cloretazine 62 Neulasta R 62 Renal Cell Carcinoma 62 LSE ASM 62 diffuse gastric 62 ® bevacizumab 62 Gleevec imatinib mesylate 62 LymphoStat B TM 62 Insegia 62 skeletal metastases 62 paclitaxel cisplatin 62 EGFR expressing metastatic colorectal 62 steroid refractory GvHD 62 resected pancreatic cancer 62 pomalidomide 62 resminostat 62 refractory multiple myeloma 62 PF # [002] 62 complete cytogenetic response 62 Genasense ® 62 trial evaluating Prochymal 62 relapsed ALL 62 figitumumab 62 ongoing Phase 1b 62 comparator arm 62 epithelial tumors 62 prostate cancer CRPC 62 achieved ACR# 62 gemcitabine Gemzar R 62 stage IIIA 62 Fludara 62 recombinant PSMA vaccine 62 ZOLINZA 62 HBeAg positive patients 62 neoadjuvant treatment 62 relapsed MCL 62 adjuvant cisplatin 62 prior chemotherapy regimens 62 Fludara ® 62 locoregional 62 HIV HCV coinfected 62 PNP inhibitor 62 phase IIa clinical 62 CR# vcMMAE 62 Waldenstrom macroglobulinemia 62 Vitaxin 62 radiation sensitizer 62 Glioblastoma multiforme GBM 62 Soft Tissue Sarcoma 62 PEGylated Fab fragment 62 ponatinib 62 orally administered inhibitor 62 Initiate Phase 62 plus prednisone 62 hoFH 62 moderate renal impairment 62 Advanced Renal Cell 62 decompensated liver disease 62 K ras mutations 62 PEG interferon 62 Tavocept 62 tyrosine kinase inhibitor TKI 62 SUCCEED trial 62 OHR/AVR# 61 hormone deprivation 61 cancer mCRC 61 Prodarsan R 61 squamous cell lung cancer 61 paclitaxel Taxol R 61 carcinoma mCRC 61 INSPIRE Trial Phase III 61 SJIA 61 T1c 61 basal cell carcinoma BCC 61 FOLOTYN ® 61 oropharyngeal candidiasis OPC 61 R sorafenib tablets 61 severe oral mucositis 61 follicular non 61 Herceptin trastuzumab 61 brain metastases originating 61 Zytiga 61 Ceflatonin R 61 cell acute lymphoblastic 61 aflibercept VEGF Trap 61 mTOR inhibitor 61 Antisoma AS# 61 KRAS mutant tumors 61 trastuzumab Herceptin ® 61 Zybrestat 61 pancreatic NET 61 myelofibrosis 61 rheumatoid arthritis psoriatic arthritis 61 HCV NS5B polymerase 61 vandetanib 61 midstage clinical 61 PI3K/Akt pathway inhibitor 61 hepatitis C genotype 61 chemoradiotherapy 61 follicular lymphomas 61 Multiple Myeloma MM 61 lymphocytosis 61 Xeloda ® 61 Achieves Primary Endpoint 61 gastrointestinal stromal tumors GIST 61 Phase 1b clinical trials 61 Elagolix 61 YONDELIS 61 Genentech Rituxan 61 acute myeloid 61 HER2 positive 61 approved incretin mimetic 61 pan HDAC inhibitor 61 dosing cohort 61 unresectable 61 HNSCC 61 transthyretin TTR mediated amyloidosis 61 receiving immunosuppressive therapy 61 Metastatic Prostate Cancer 61 evaluating Prochymal 61 colorectal carcinoma 61 bortezomib Velcade R 61 Asentar 61 orally inhaled migraine 61 Advaxis Phase 61 ovarian carcinoma 61 MEK Inhibitor 61 small lymphocytic lymphoma 61 receiving highly emetogenic 61 metastatic bone 61 null responder 61 ovarian prostate 61 leukemia CLL 61 abiraterone 61 selective angiogenic kinase inhibitor 61 rindopepimut 61 grade cervical intraepithelial 61 TNF antagonist 61 CHOP chemotherapy 61 Acute Exacerbations 61 TREANDA 61 myelogenous leukemia 61 orthotopic model 61 Telintra 61 sapacitabine 61 chronic myeloid 61 relapsed CLL 61 Camptosar ® 61 Chronic Myeloid Leukemia 61 PSADT 61 Fludarabine 61 GetGoal Phase III 61 lymphocytic leukemia 61 MCSP respectively 61 leukaemias 61 colorectal bladder 61 modified glutathione analog 61 preoperative chemotherapy 61 RhuDex ™ 61 docetaxel chemotherapy 61 Clevudine 61 localized renal 61 Tramiprosate ALZHEMED TM 61 relapsed Acute Myeloid 61 sarcomatoid 61 pancreatic colon 61 pegylated liposomal doxorubicin PLD 61 VNP#M 61 ANCHOR trial 61 liver metastasis 61 superficial bladder cancer 61 Infusion reactions 61 dasatinib 61 multicenter Phase 61 myelofibrosis MF 61 FluCAM 61 resistant ovarian cancer 61 Nexavar ® 61 untreated multiple myeloma 61 Sprycel dasatinib 61 invasive lobular carcinoma 61 aplastic anemia AA 61 recurrent genital herpes 61 CD# CEA 61 Myelodysplastic Syndrome 61 verteporfin 61 Tykerb lapatinib 61 TORISEL 61 myocardial infarction ventricular fibrillation 61 HuMax CD4 61 sarcoma melanoma 61 dermatology biopharmaceutical company 61 hA# 61 Irinotecan 61 intravenous belinostat 61 immune thrombocytopenic purpura ITP 61 proliferative retinopathy 61 Newly Diagnosed Multiple Myeloma 61 following fluoropyrimidine oxaliplatin 61 muscular dystrophy cystic fibrosis 61 dose escalation clinical 61 NSABP C 61 Vidaza ® 61 Idiopathic Pulmonary Fibrosis 61 Canvaxin 61 plus dexamethasone 61 adjuvant colon cancer 61 cEVR 61 baminercept 61 standard chemotherapy regimen 61 cytarabine daunorubicin 61 tramiprosate Alzhemed TM 61 Celgene Revlimid 61 HeFH 61 vemurafenib 61 Fibrillex TM 61 Platinum Resistant Ovarian 61 histologic subtype 61 ASH Abstract # 61 retinal vein occlusion induced 61 Allovectin 7 ® 61 infliximab monotherapy 61 cirrhosis liver failure 61 resectable 61 adriamycin 61 PTK# 61 ALN PCS 61 Arch Intern Med 61 hour bronchodilation 61 trabedersen 61 oral nucleoside analogue 61 diseases fat malabsorption 61 RANK Ligand inhibitor 61 HRPC ovarian cancer 61 colorectal lung 61 tenofovir emtricitabine 61 MPS IVA 61 remission induction 61 ATL# [001] 61 Telatinib 61 carboplatin paclitaxel 61 LUX Lung 61 constipation OIC 61 Provectus Pharmaceuticals specializes 61 doxorubicin cyclophosphamide 61 PD LID 61 refractory anaplastic astrocytoma 61 pediatric pontine glioma 61 anti angiogenic therapy 61 phase Ib 61 decitabine 61 Proxinium TM 61 tyrosine kinase inhibitors TKIs 61 HER2 positive breast cancer 61 Relapsed Refractory Multiple Myeloma 61 coinfected patients 61 refractory indolent non 61 allogeneic HSCT 61 refractory gastrointestinal stromal 61 castration resistant prostate cancer 61 BCR ABL inhibitor 61 Pulmonary Arterial Hypertension PAH 61 ORENCIA ® 61 non myeloid malignancies 61 rasagiline tablets 61 formerly LymphoStat B 61 FLT3 mutations 61 toenail onychomycosis 61 huC# DM4 61 RhuDex ® 61 HER2 expression 61 Taxotere docetaxel 61 tolevamer 61 PDE# inhibitors 61 gastrin analogue TT 61 HGS ETR2 61 ALN TTR 61 heavily pretreated patients 61 Treanda 61 Panzem R 61 Amgen Vectibix 61 Ozarelix 61 Retreatment 61 RoACTEMRA 61 Severe Sepsis 61 nilotinib Tasigna ® 61 null responder HCV 61 EFAPROXYN 61 metastatic liver 61 farletuzumab 61 symptomatic BPH 61 VALSTAR TM 61 prostate carcinoma 61 tesetaxel 61 Phase Ib clinical 61 gemcitabine Gemzar 61 thymoma 61 investigational therapies 61 evaluating mipomersen 61 BRCA deficient 61 talactoferrin 61 non CF bronchiectasis 61 pharmacogenomic translational research 61 Lymphocytic 61 BZL# 61 alemtuzumab treated 61 refractory prostate cancer 61 FUSILEV enhances 61 recurrent glioma 61 ILUVIEN ® 61 trial evaluating PRX# 61 metastatic HER2 negative 60 ipsilateral breast 60 Safinamide 60 Virulizin R 60 Femara letrozole 60 neoadjuvant therapy 60 myelodysplastic syndromes 60 investigational immunotherapy 60 BENLYSTA ® 60 antibody MT# 60 drug GAP #B# 60 underwent prostate biopsy 60 chronic thromboembolic pulmonary 60 heFH 60 temozolomide TMZ 60 CRp 60 KSP inhibitor 60 Pirfenidone 60 acute myelogenous leukemia AML 60 Patients Treated With 60 SYN# 60 AEGR 60 seminoma 60 Arimidex anastrozole 60 dexanabinol 60 HER2 overexpression 60 rALLy clinical trial 60 refractory myeloma 60 docetaxel Taxotere ® 60 Chronic Lymphocytic Leukemia 60 #mg BID [001] 60 Nicole Onetto MD 60 Golimumab 60 biochemical relapse 60 HBeAg + 60 #mg dosing group 60 DEB# 60 prostate adenocarcinoma 60 standard chemotherapy regimens 60 autoantibody positive 60 generation DACH Platinum 60 transplantation HCT 60 initiate Phase 1b 60 IMGN# 60 IL# PE#QQR 60 inhibitor RG# 60 Elotuzumab 60 AQ4N 60 CEQ# 60 KRAS mutant 60 ribavirin therapy 60 OvaRex ® MAb 60 chronic HCV 60 PEG PAL 60 SinuNase TM 60 oral deforolimus 60 acetonide FA 60 patients coinfected 60 HCV RESPOND 2 60 zanolimumab 60 lenalidomide dexamethasone 60 esophageal candidiasis 60 diabetic neuropathic pain 60 mcg albinterferon alfa 2b 60 genotype 1b 60 cilengitide 60 XL# administered orally 60 Paclitaxel Carboplatin 60 trabectedin 60 azilsartan medoxomil 60 humanised monoclonal antibody 60 immunomodulatory therapy 60 de novo AML 60 Epratuzumab 60 Antitumor Activity 60 thalidomide Thalomid 60 albiglutide currently 60 HGS ETR1 mapatumumab 60 Phase IIb clinical trials 60 catheter occlusion 60 agonistic human 60 HDAC Inhibitor 60 BrachySil TM 60 ® bortezomib 60 Onalta ™ 60 L MTP PE 60 alpha1 antitrypsin deficiency 60 HER2 negative 60 endocrine therapies 60 Menopausal hormone therapy 60 cediranib 60 nilotinib 60 Phase Ib study 60 ASCO GI 60 CDK cyclin dependent 60 Aloxi injection